Skip to main content

Cancer Chemotherapy and Pharmacology

Ausgabe 1/2014

Inhalt (21 Artikel)

Review Article

Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories

Lei Cheng, Wei Ren, Li Xie, Ming Li, Jiang Liu, Jing Hu, Bao-Rui Liu, Xiao-Ping Qian

Original Article

A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors

Hiroshi Wakui, Noboru Yamamoto, Satoru Kitazono, Hidenori Mizugaki, Shinji Nakamichi, Yutaka Fujiwara, Hiroshi Nokihara, Yasuhide Yamada, Kohei Suzuki, Hironori Kanda, Shiro Akinaga, Tomohide Tamura

Original Article

Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent

Ying Yi Chen, Pradeep B. Lukka, Wayne R. Joseph, Graeme J. Finlay, James W. Paxton, Mark J. McKeage, Bruce C. Baguley

Original Article

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Hidehito Horinouchi, Noboru Yamamoto, Hiroshi Nokihara, Takeshi Horai, Makoto Nishio, Fumiyoshi Ohyanagi, Atsushi Horiike, Kazuhiko Nakagawa, Masaaki Terashima, Takafumi Okabe, Hiroyasu Kaneda, Mark D. McKee, Dawn M. Carlson, Hao Xiong, Tomohide Tamura

Original Article

Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans

Eleftheria Tsakalozou, Eyob D. Adane, Yali Liang, Susanne M. Arnold, Markos Leggas

Original Article

Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers

Markus Zollinger, Frédéric Lozac’h, Eunju Hurh, Corinne Emotte, Hounayda Bauly, Piet Swart

Original Article

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

Devalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, Jordi Rodon, Kamalesh Sankhala, Alain Mita, Daniel Benjamin, Norma Ketchum, Joel Michalek, Anthony Tolcher, John Wright, John Sarantopoulos

Original Article

Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia

Ali-Akbar Golabchifar, Saeed Rezaee, Ardeshir Ghavamzadeh, Kamran Alimoghaddam, Nahid Mobarghei Dinan, Mohammad-Reza Rouini

Original Article

Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics

Yi Gu, Jian Wang, Ke Li, Li Zhang, Hongcan Ren, Lixia Guo, Yang Sai, Weihan Zhang, Weiguo Su

Original Article

A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

Autumn J. McRee, Janine M. Davies, Hanna G. Sanoff, Richard M. Goldberg, Stephen Bernard, E. Claire Dees, Kimberly Keller, Anastasia Ivanova, Bert H. O’Neil

Original Article

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Johanna C. Bendell, David S. Hong, Howard A. Burris III, Aung Naing, Suzanne F. Jones, Gerald Falchook, Patricia Bricmont, Agnes Elekes, Edwin P. Rock, Razelle Kurzrock

Original Article

A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer

Patricia Roxburgh, Graeme R. Lumsden, James Paul, Sharon Harden, Lorna Sweeting, Allan James, Adrian Crellin, Rosemary Morrison, T. R. Jeffry Evans, Alexander C. McDonald

Original Article

Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer

Marine Jary, Francois Ghiringhelli, Marion Jacquin, Francine Fein, Thierry Nguyen, Denis Cleau, Virginie Nerich, Maryame El Gani, Pierre Mathieu, Séverine Valmary-Degano, Laurent Arnould, Catherine Lassabe, Najib Lamfichekh, Serge Fratté, Sophie Paget-Bailly, Franck Bonnetain, Christophe Borg, Stefano Kim

Open Access Original Article

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

Wendi V. Rodrigueza, Michael J. Woolliscroft, Abdul-Shukkur Ebrahim, Robert Forgey, Patrick J. McGovren, Gerold Endert, Andreas Wagner, Danielle Holewa, Amro Aboukameel, Richard D. Gill, Charles L. Bisgaier, Richard A. Messmann, Christopher E. Whitehead, Elzbieta Izbicka, Robert Streeper, Michael C. Wick, Gabriela Stiegler, C. A. Stein, David Monsma, Craig Webb, Mina P. Sooch, Steffen Panzner, Ramzi Mohammad, Neal C. Goodwin, Ayad Al-Katib

Original Article

Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells

Han Min, Min Xu, Zhi-rong Chen, Jun-dong Zhou, Min Huang, Kai Zheng, Xiao-ping Zou

Original Article

Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)

Rathi N. Pillai, Joseph Aisner, Suzanne E. Dahlberg, John S. Rogers, Robert S. DiPaola, Seena Aisner, Suresh S. Ramalingam, Joan H. Schiller

Original Article

Irinotecan and temozolomide brain distribution: a focus on ABCB1

Lauriane Goldwirt, Kevin Beccaria, Alexandre Carpentier, Robert Farinotti, Christine Fernandez

Clinical Trial Report

Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors

Monica Mita, Michael Gordon, Lee Rosen, Nirmal Kapoor, Gavin Choy, Sanjeev Redkar, Pietro Taverna, Aram Oganesian, Amarpal Sahai, Mohammad Azab, Robert Bristow, Anthony W. Tolcher

Clinical Trial Report

Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer

Yixing Jiang, Heath B. Mackley, Eric T. Kimchi, Junjia Zhu, Niraj Gusani, Jussuf Kaifi, Kevin F. Staveley-O’Carroll, Chandra P. Belani

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.